Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Result of the auction of treasury bills on 30 May 2024
-
Metasphere Labs Appoints Dustin Muscato as Advisor for Carbon Credit Protocol Initiative
-
Crossject announces publication of clinical data on ZEPIZURE ® in Neurology and Therapy
-
Delphos Advises MPC Energy Solutions on a USD 34 million Non-Recourse Project Financing for the Construction of a 66MWp Solar PV plant in Guatemala
-
Fortude and Accure join forces to enhance Infor M3 and CloudSuite experience for Europe
-
Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board
-
Share Buyback Transaction Details May 23 – May 29, 2024
-
Form 8.5 (EPT/RI) - musicMagpie Plc
-
Form 8.5 (EPT/RI) - Trinity Exploration & Production Plc
-
Form 8.5 (EPT/RI) - Touchstone Exploration Inc
-
Form 8.5 (EPT/RI) - NewRiver REIT Plc
-
Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
-
New prices for natural gas transmission services have been approved
-
Persistent Systems Selects Zscaler to Launch Technology Modernization and Renewable Energy Initiatives
-
Curium Announces First Commercial Doses in France of Pylclari® – an Innovative 18F-Psma Pet Tracer Indicated in Patients With Prostate Cancer
-
Changes in organisational structure and management team of Telia Lietuva
-
Green Bioactives Reports Remarkable Cognitive Benefits of its Newly Launched Memory-boosting Nutraceutical Product, GBL-Memory¹
-
Interim financial report for 1 January - 31 March 2024 for FirstFarms A/S
-
Green Bioactives Reports Remarkable Cognitive Benefits of its Newly Launched Memory-boosting Nutraceutical Product, GBL-Memory¹
-
VINCI wins new works contract for Melbourne Airport in Australia
-
Form 8.5 (EPT/RI) - Renalytix plc
-
Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals
-
Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals
-
Samsung Bioepis to Present Post-hoc Analysis of Phase 3 Study for EPYSQLI™ (SB12; Eculizumab Biosimilar), at the European Hematology Association (EHA) Congress 2024
-
Nxera Pharma and PrecisionLife Expand Strategic R&D Partnership into New Therapeutic Area
-
BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’s disease cell therapy candidate bemdaneprocel
-
Hoylu AB Publishes the Interim Report for January – March 2024
-
Nxera Pharma and PrecisionLife Expand Strategic R&D Partnership into New Therapeutic Area
-
Survey shows that most Finns are satisfied with their own recycling habits - people aged over 65 have a more positive attitude towards recycling than young people
-
Statement of total voting rights and shares forming the company’s share capital as of May 13, 2024
-
Combined General Meeting of June 20, 2024 - Availability of the preparatory documents
-
Change of Company name and ticker symbol on Euronext Paris
-
Renewi announces sale of UK Municipal business to Biffa
-
Galantas Report Financial Results for the Quarter Ended March 31, 2024
-
PRESS RELEASE: BIGBEN WEEK 2024: NACON PRESENTS AN AMBITOUS LINE-UP AND ANNOUNCES A NEW DEPARTMENT DEDICATED TO RACING
-
[Press Release] The iliad Group records solid first-quarter results
-
FY24 Full Year Results, Delivering on Commitments
-
Endeavour Announces Wet Commissioning is Underway at Lafigué Project
-
ZETADISPLAY AB (publ) INTERIM REPORT 1 JANUARY – 31 MARCH 2024
-
Intention to raise further funds
-
Transaction in Own Shares
-
Unaudited interim results for the three-month period ended 31 March 2024
-
-
Moody’s selects TomTom location data for its risk management solutions
-
Azerion publishes interim Q1 2024 results
-
Azerion announces expansion of its Executive Committee and new responsibilities
-
BGHL (GBP): NAV(s)
-
BGHL (EUR): NAV(s)
-
BUREAU VERITAS - Availability of preparatory documents for Bureau Veritas’ Ordinary Shareholders’ Meeting of June 20, 2024
-
FRO – First Quarter 2024 Results

